OTCMKTS:PVCT

Provectus Biopharmaceuticals (PVCT) Stock Forecast, Price & News

$0.13

+0.01 (+8.44%)

(As of 06/5/2023 ET)

Compare

Today's Range: $0.12
▼
$0.13
50-Day Range: $0.12
▼
$0.17
52-Week Range: $0.03
▼
$0.19

Volume: 123,489 shs
Average Volume: 105,782 shs
Market Capitalization: $53.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Financials Insider Trades Headlines SEC Filings Short Interest

About Provectus Biopharmaceuticals (OTCMKTS:PVCT) Stock

Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company, which engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treat several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The company was founded by Eric A. Wachter in 2002 and is headquartered in Knoxville, TN.

Receive PVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PVCT Stock News Headlines

June 3, 2023 | finance.yahoo.com

PVCT - Provectus Biopharmaceuticals, Inc.

May 27, 2023 | americanbankingnews.com

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Up 13,466.7% in May

June 6, 2023 | Edge On The Street (Ad)

How to Invest in AI's Fast-Growing Market

The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.

May 12, 2023 | chron.com

Provectus: Q1 Earnings Snapshot

April 20, 2023 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Publication of Activity of Pharmaceutical-Grade Rose Bengal Sodium (RBS) Against Colistin-Resistant Gram-Negative Bacteria

April 18, 2023 | technews.tmcnet.com

Hucu.ai and Provectus expand their relationship into a multi-year partnership

April 16, 2023 | americanbankingnews.com

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

March 29, 2023 | marketwatch.com

Lyophilization Services for Biopharmaceuticals Market Growing Demand and Trends 2023 to 2031

June 6, 2023 | Edge On The Street (Ad)

ChatGPT Is Already "Old School"

As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.

March 27, 2023 | marketwatch.com

Biopharmaceutical Third Party Logistics (3PL) Market Growth and Competitive Landscape 2023-2029

March 21, 2023 | venturebeat.com

Former Estée Lauder Executive Joins Provectus Algae as Cosmetics Advisor Signalling Industry Expansion

March 17, 2023 | forbes.com

Five Areas Where AI Is Revolutionizing The Biopharmaceutical Industry

March 1, 2023 | venturebeat.com

Provectus Algae Receives Strategic Investment from Biotech Leader CJ Bio

February 26, 2023 | nasdaq.com

Relative Strength Alert For Day One Biopharmaceuticals

February 19, 2023 | marketwatch.com

Biopharmaceutical Third Party Logistics (3PL) Market Size 2023 Will Touch A New Level In The Upcoming Year 2026

January 24, 2023 | benzinga.com

Short Volatility Alert: Provectus Biopharm

January 9, 2023 | finance.yahoo.com

Provectus Biopharmaceuticals Releases 2023 Stockholder Letter

December 31, 2022 | thestreet.com

NYSE Places Provectus Listing Status Under Review

December 12, 2022 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023

December 1, 2022 | finance.yahoo.com

Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022

November 10, 2022 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022

November 2, 2022 | finance.yahoo.com

Provectus Biopharmaceuticals Announces World Health Organization Selection of “Rose Bengal Sodium” as International Nonproprietary Name for Active Pharmaceutical Ingredient

October 26, 2022 | nz.finance.yahoo.com

Provectus Algae Strengthens R&D Team, Reinforcing Commitment to Delivering Sustainable Synbio Solutions

October 25, 2022 | finance.yahoo.com

Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation

October 20, 2022 | finance.yahoo.com

Provectus Biopharmaceuticals, Inc. (PVCT)

September 29, 2022 | finance.yahoo.com

Provectus Biopharmaceuticals Establishes Research Collaboration with University of Texas Medical Branch at Galveston to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal for Wound Healing

September 21, 2022 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Exclusive License Option Agreement with Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at University of Miami for Treatment of Eye Infections

See More Headlines

PVCT Price History

30 days | 90 days | 365 days | Advanced Chart

PVCT Company Calendar

Today: 6/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:PVCT
Previous Symbol: NYSEMKT:PVCT
CUSIP: N/A
CIK: 315545
Web: www.provectusbio.com
Phone: (866) 594-5999
Fax: 866-998-0005
Employees: 2
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-3,560,000.00
Net Margins: -333.07%
Pretax Margin: -332.97%
Return on Equity: N/A
Return on Assets: -162.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.18
Quick Ratio: 0.18

Sales & Book Value

Annual Sales: $990,000.00
Price / Sales: 54.45
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.01) per share
Price / Book: -12.85

Miscellaneous

Outstanding Shares: 419,500,000
Free Float: 383,001,000
Market Cap: $53.91 million
Optionable: Not Optionable
Beta: 0.47

Key Executives

Bruce Horowitz
Chief Operating Officer & Director

Heather Raines
Chief Financial Officer

Eric A. Wachter
Chief Technology Officer

Key Competitors

View All Competitors

PVCT Stock - Frequently Asked Questions

How have PVCT shares performed in 2023?: Provectus Biopharmaceuticals' stock was trading at $0.1083 at the beginning of 2023. Since then, PVCT shares have increased by 18.7% and is now trading at $0.1285.
View the best growth stocks for 2023 here.
Are investors shorting Provectus Biopharmaceuticals?: Provectus Biopharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 81,400 shares, an increase of 13,466.7% from the April 30th total of 600 shares. Based on an average daily volume of 216,200 shares, the short-interest ratio is currently 0.4 days.
View Provectus Biopharmaceuticals' Short Interest.
What other stocks do shareholders of Provectus Biopharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Provectus Biopharmaceuticals investors own include Vertex Energy (VTNR), Good Times Restaurants (GTIM), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONC), Cytori Therapeutics (CYTX), (DARA) (DARA), Energy Transfer (ET), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB) and MaxLinear (MXL).
What is Provectus Biopharmaceuticals' stock symbol?: Provectus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "PVCT."

How do I buy shares of Provectus Biopharmaceuticals?: Shares of PVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Provectus Biopharmaceuticals' stock price today?: One share of PVCT stock can currently be purchased for approximately $0.13.
How much money does Provectus Biopharmaceuticals make?: Provectus Biopharmaceuticals (OTCMKTS:PVCT) has a market capitalization of $53.91 million and generates $990,000.00 in revenue each year.
How can I contact Provectus Biopharmaceuticals?: Provectus Biopharmaceuticals' mailing address is 10025 INVESTMENT DRIVE SUITE 250, KNOXVILLE TN, 37932. The official website for the company is www.provectusbio.com. The company can be reached via phone at (866) 594-5999, via email at investorrelations@pvct.com, or via fax at 866-998-0005.

This page (OTCMKTS:PVCT) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial